Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prexasertib - Acrivon Therapeutics/SOM Biotech

Next Previous
Drug Profile

Prexasertib - Acrivon Therapeutics/SOM Biotech

Alternative Names: ACR 368; Captisol® enabled prexasertib; LY 2606368 MsOH H2O; LY-2606368; Prexasertib Mesylate Monohydrate - Acrivon Therapeutics/ SOM Biotech

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Array BioPharma; Eli Lilly and Company
  • Developer Acrivon Therapeutics; Children's Oncology Group; Dana-Farber Cancer Institute; Eli Lilly and Company; Ewha Womans University; National Cancer Institute (USA); SOM Biotech
  • Class Antineoplastics; Antivirals; Nitriles; Pyrazines; Pyrazoles; Small molecules
  • Mechanism of Action Checkpoint kinase 1 inhibitors; Checkpoint kinase 2 inhibitors; Coronavirus-3C-like-proteinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Anal cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Bladder cancer; Endometrial cancer; Ovarian cancer; Solid tumours; Squamous cell cancer
  • Phase I/II Urogenital cancer
  • Preclinical COVID 2019 infections
  • Discontinued Acute myeloid leukaemia; Colorectal cancer; Fallopian tube cancer; Head and neck cancer; Myelodysplastic syndromes; Non-small cell lung cancer; Peritoneal cancer; Prostate cancer; Small cell lung cancer; Triple negative breast cancer

Most Recent Events

  • 25 Sep 2023 Phase-II clinical trials in Endometrial cancer (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (IV) (Acrivon Therapeutics pipeline, September 2023)
  • 09 May 2023 Prexasertib - Acrivon Therapeutics/SOM Biotech receives Fast Track designation for Endometrial cancer [IV] (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA
  • 09 May 2023 Prexasertib - Acrivon Therapeutics/SOM Biotech receives Fast Track designation for Ovarian cancer (Monotherapy, Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top